A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.
about
Vaccines for gonorrhea: can we rise to the challenge?A novel self-replicating chimeric lentivirus-like particleAlphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationAttenuated vesicular stomatitis viruses as vaccine vectorsA single amino acid change in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus S.A.AR86.Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsRecombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice.Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challengeExpression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region.An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal miceExpression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons.Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system.Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression systemRibosomal protein S6 associates with alphavirus nonstructural protein 2 and mediates expression from alphavirus messagesHumoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.Viral alteration of cellular translational machinery increases defective ribosomal products.Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primatesVenezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.Alphavirus-based expression vectors: strategies and applications.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector systemTemplate-dependent initiation of Sindbis virus RNA replication in vitro.Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.Nuclear import and export of Venezuelan equine encephalitis virus nonstructural protein 2.
P2860
Q21131153-AEE36A0D-A334-4D71-A917-92DFC5DF7482Q24611993-9CDB4E17-B0A4-4D80-B95F-A3F4DB2E08E7Q24634730-38DA4505-6CE8-4E82-8FCD-E27EFEE0B43FQ27469358-7E30866E-166A-465B-AD7D-AD43AE7B736BQ27469656-9532B57A-D06C-403D-85FD-B9C03B37D5C3Q33737723-6C7ACE34-1C77-4A5D-B646-BB714B13957DQ33783688-6BAEC1C3-33EF-4B6A-8B0E-4FB20C653B95Q33783986-BBCC0421-39E8-4D23-A430-7087D6019BBAQ33787304-63BB5D94-2227-4D15-A8ED-E166412566AEQ33796546-81B13FF3-FBA9-40D4-9565-B5FDDAC0FF9AQ33850032-FB1BF12D-0D21-4F35-8095-5F8348F45F39Q33851223-E113DE3D-9D2C-4D64-9F26-D890D33B0EF8Q34059308-E7510FAF-C235-467A-837D-34261E3FBE51Q34332253-BC6BFD6D-F01C-4CD5-B374-AE33FF4A7A07Q34335296-EA6315E0-2F3F-4069-9CFB-10D16BEEC753Q34357038-884A8808-89B3-483B-850B-1DE361ECCA57Q34545923-BF3DBA0C-1B39-4788-A704-287E2DF7D966Q34754733-A443394F-B177-4138-9BE3-C2A5058D48B1Q35023689-2BB75775-DF18-4042-BFF9-A0EF9E7A0A75Q35881081-9D12CC35-0993-4F73-997E-9102DE862580Q35914423-AD95FA08-F1ED-4329-AE63-CBF034B482ACQ36315159-73E30654-3B27-4811-B9A4-61BFEBA35BC1Q36515541-DDD788F0-0354-41ED-B535-54B4CB16E368Q36759944-386436EC-341B-474E-BF2E-93CFC619003CQ37250563-E56AFB98-82F3-41E4-95D4-78D25FB2BE15Q37297052-831CBF55-B2D4-4617-AE89-9318B701876FQ38839675-055DC1F0-215F-456E-A6E7-31C6D6E3601EQ39521997-45508DAC-F583-4D64-9696-F8DAE11C9C42Q39579511-B2B52B67-BC50-4A28-9DF8-039E3BCDA2F5Q39588679-05E4EE5E-2A62-4A36-90E7-5CD8B31A59A9Q42638468-C8064EF8-6F13-4A95-9D06-D5D54B830356
P2860
A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
A viral vaccine vector that ex ...... cts against mucosal challenge.
@ast
A viral vaccine vector that ex ...... cts against mucosal challenge.
@en
type
label
A viral vaccine vector that ex ...... cts against mucosal challenge.
@ast
A viral vaccine vector that ex ...... cts against mucosal challenge.
@en
prefLabel
A viral vaccine vector that ex ...... cts against mucosal challenge.
@ast
A viral vaccine vector that ex ...... cts against mucosal challenge.
@en
P2093
P2860
P1433
P1476
A viral vaccine vector that ex ...... ects against mucosal challenge
@en
P2093
R E Johnston
P2860
P304
P407
P577
1996-06-01T00:00:00Z